

Adverse perinatal outcomes associated with elevated blood pressure & stage 1 HTN

Martha Tesfalul¹, Jeffrey D. Sperling², Cinthia Blat¹, Nisha Parikh³, Juan Gonzalez Velez¹, Marya Zlatnik¹, Mary E. Norton¹

¹Department of Obstetrics, Gynecology, and Reproductive Health Sciences, University of California, San Francisco; ²Department of Obstetrics & Gynecology, Kaiser Permanente, Modesto; ³Department of Medicine, University of California, San Francisco

Background

- In 2017, the American College of Cardiology (ACC) & American Heart Association (AHA)
- reclassified BP in non-pregnant adults to the following: *Normal:* Systolic (SBP) <120 & Diastolic (DBP) <80 *Elevated BP:* SBP 120–129 & DBP <80 **Stage 1 HTN:** SBP 130–139 OR DBP 80–89 **Stage 2 HTN:** SBP ≥140 mmHg OR DBP ≥90
- Implications of these categories in pregnancy are still unclear

Objective

• To evaluate the association of the ACC/AHA BP categories of elevated BP & stage 1 HTN with adverse obstetric & perinatal outcomes

Study Design

- Retrospective cohort study
- ACC/AHA BP category assigned based on highest SBP & DBP prior to 20 weeks
- Pregnancies with elevated BP and stage 1 HTN each compared to pregnancies with normal BPs
- Inclusion criteria: singleton pregnancy, ≥ 1 BP prior to 20 weeks, delivery between 1/2014 & 10/2017
- Exclusion criteria: prior diagnosis of chronic HTN, autoimmune or chronic renal disease, fetal anomalies
- Outcomes: gestational HTN, preeclampsia, preterm birth (PTB), neonatal intensive care admission, perinatal death

Results

- After adjusting for relevant covariates, elevated BP & stage 1 HTN associated with a higher risk of preeclampsia & severe preeclampsia
- Stage 1 HTN associated with PTB & perinatal death

Conclusion

- Patients with elevated BP & stage 1 HTN prior to 20 weeks are at increased risk of adverse outcomes
- Further research needed to determine optimal care of patients with elevated BP & stage 1 HTN in pregnancy

Questions? Take a picture of this QR code to access the poster or email Dr. Tesfalul at Martha.Tesfalul@UCSF.edu.

The 2017 ACC/AHA reclassified blood pressure categories identify patients with increased risk of preeclampsia, preterm birth, and perinatal death.



Table
Outcom
No

	Normal BP	Elevated BP		
	N = 3,489	N = 1,369		
	n (%)	n (%)	aRR (CI)	
Maternal Outcomes				
Gestational HTN	250 (7.2%)	247 (18.0%)	2.2 (1.9-2.6)	
Preeclampsia	198 (5.7%)	160 (11.7%)	1.8 (1.4-2.2)	
Severe features	107 (3.1%)	78 (5.7%)	1.6 (1.2-2.2)	
Neonatal Outcomes				
Preterm Birth				
< 37 wks	181 (5.1%)	88 (6.4%)	1.2 (0.9-1.5)	
< 34 wks	47 (1.4%)	20 (1.5%)	1.3 (0.7-2.2)	
SGA	443 (12.7%)	147 (10.7%)	0.9 (0.7-1.1)	
NICU admission	390 (11.2%)	196 (14.3%)	1.2 (1.0-1.4)	
Perinatal death	13 (0.4%)	7 (0.5%)	1.2 (0.4-3.3)	
IUFD	11 (0.3%)	2 (0.2%)	0.5 (0.1-2.1)	
Neonatal death	2 (0.1%)	5 (0.4%)	1.8 (0.6-5.4)	

 Table 2. Maternal & Neonatal

Outcomes of Pregnancies with Normal BP vs *Stage 1 HTN*

	Normal BP N = 3,489	Stage 1 HTN N = 1,092		
	n (%)	n (%)	aRR (CI)	
Maternal Outcomes				
Gestational HTN	250 (7.2%)	260 (23.8%)	2.8 (2.3-3.3)	
Preeclampsia	198 (5.7%)	164 (15.0%)	2.1 (1.7-2.6)	
Severe features	107 (3.1%)	75 (6.8%)	1.8 (1.3-2.4)	
Neonatal Outcomes				
Preterm Birth				
< 37 wks	181 (5.1%)	86 (7.9%)	1.4 (1.1-1.9)	
< 34 wks	47 (1.4%)	25 (2.0%)	1.5 (0.9-2.6)	
SGA	443 (12.7%)	132 (12.1%)	0.9 (0.8-1.2)	
NICU admission	390 (11.2%)	151 (14.6%)	1.2 (1.0-1.4)	
Perinatal death	13 (0.4%)	8 (0.7%)	2.8 (1.2-6.3)	
IUFD	11 (0.3%)	6 (0.6%)	2.1 (0.6-7.1)	
Neonatal death	2 (0.1%)	2 (0.2%)	2.4 (0.8-7.4)	

aRR, adjusted relative risk compared to normotensive patients adjusted for maternal age, nulliparity, race, body mass index, in vitro fertilization, tobacco use, pregestational diabetes, and aspirin use; CI, 95% confidence interval



University of California San Francisco

1. Maternal & Neonatal nes of Pregnancies with ormal BP vs *Elevated BP*